HST Global Announces Strategic Alliance for R&D

HST Global Announces a Strategic Alliance with World-Renowned Doctor for Product
Research and Development
HAMPTON, Va.--(Business Wire)--
HST Global, Inc. (OTCBB: HSTC) today announced a strategic R&D alliance with Dr.
James W. Forsythe for the research and development of HST`s exclusive
Nutraceutical and Medical Food formulation platform. Dr. Forsythe brings over
thirty years of medical and research experience including expertise in the
research and clinical application of Nutraceutical and Medical Food products.

"Dr. Forsythe`s well established experience in the medical community will be a
valuable asset in the development of our exclusive brand of products," said Ron
Howell, CEO and President of HST Global, Inc. "James will be instrumental in the
acquisition of new technologies in the emerging field of science-based
Nutraceuticals." Dr. Forsythe is a past Associate Professor of Medicine and
Pathology, University of Nevada Medical School Reno, NV. Prior to that, he was
an instructor in Medicine and Hematology, University of California Medical
Center, San Francisco, CA.

Dr. Forsythe currently serves on HST Global Inc.`s Scientific Advisory Board. He
received his Doctorate of Medicine from the University of California, San
Francisco and his Undergraduate Degree from University of California at
Berkeley. Dr. Forsythe is certified in Homeopathy and Board Certified in
Internal Medicine, Medical Oncology and Utilization Review and Quality
Assurance. He is also Board eligible in Clinical Pathology and Medical
Gerontology. Dr. Forsythe is also the owner and Medical Director of Cancer
Screening and Treatment Center of Nevada and Century Wellness Clinic. In
addition, Dr. Forsythe spent 26 years in the United States Army Medical Corps,
retiring full Colonel. He was also the former State Surgeon in the Nevada Army
National Guard.

Through a proprietary scientific platform, HST is developing therapies that
address metabolic deficiencies through the application of either proprietary or
Patent-Pending Nutraceutical technologies, or where appropriate, Medical Food
products. Medical Food products are FDA-regulated products, in a relatively new
category of medical protocols defined by Congress as part of the Orphan Drug
Act. Medical Food products are formulated for administration under the
supervision of a physician and are intended for the specific dietary management
of a disease or condition based on recognized scientific principles and
established by medical evaluation. Medical Foods can be prescription products,
but are different than drugs or dietary supplements in several aspects, such as
their claims. Claims for both Medical Foods and drugs must be supported by solid
laboratory and clinical data.

About HST Global, Inc.

HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that
is developing and or acquiring a network of Wellness Centers worldwide that are
primarily focused on the immunotherapy and alternative treatment of late stage
cancer. In addition, the company intends to acquire innovative products for the
treatment of late stage cancer. In this regard, the company primarily focuses on
immunotherapy and alternative product candidates that are undergoing or have
already completed significant clinical testing for the treatment of late stage
cancer.

HST Global, Inc. wishes to inform readers that forward-looking statements in
this release are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Readers are cautioned that such
forward looking statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and development
activities and in clinical trials by others; possible acquisitions of other
technologies, assets or businesses; possible actions by customers, suppliers,
competitors, regulatory authorities; and other risks detailed from time to time
in the Company's periodic reports filed with the Securities and Exchange
Commission.

HST Global, Inc.
Investor Relations:
David Nesbitt, 757-766-6100
ir@hstglobal.com
www.hstglobal.com

Copyright Business Wire 2009